Dr. Donald P. Quick, MD
Hematology & Oncology (Hematology & Oncology Physician)
4101 22nd Place
Lubbock, TX 79410
Who else practices at this address →
Lubbock County includes primary care (7% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 534
Licensed in Texas since 1983, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license G3711 (first issued 1983; active) · NM license MD2005-0751
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Covenant Medical Center Lubbock, TX
- Covenant Childrens Hospital Lubbock, TX
- Nor-Lea Hospital District Lovington, NM
- Artesia General Hospital Artesia, NM
- Covenant Hospital Plainview Plainview, TX
Medical groups
- Covenant Medical Group (233 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 534
- Services billed
- 1,320
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 365 | 162 |
| Established patient office or other outpatient visit, 20-29 minutes | 288 | 208 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 152 | 60 |
| New patient office or other outpatient visit, 30-44 minutes | 66 | 66 |
| New patient office or other outpatient visit, 45-59 minutes | 49 | 49 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 29 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 23 | 20 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Lubbock, TX | 215 |
| Acyclovir Other prescribers in Lubbock, TX | 178 |
| Dexamethasone Other prescribers in Lubbock, TX | 106 |
| Lenalidomide | 103 |
| Hydroxyurea Other prescribers in Lubbock, TX | 86 |
| Brukinsa (zanubrutinib) | 57 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Lubbock, TX | 49 |
| Venclexta (venetoclax) | 41 |
| Xarelto (rivaroxaban) Other prescribers in Lubbock, TX | 37 |
| Imbruvica (ibrutinib) | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 30 payments worth $735 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $126 |
|---|---|
| Genentech USA, Inc. | $88.91 |
| Pfizer Inc. | $76.67 |
| Janssen Biotech, Inc. | $65.27 |
| Novartis Pharmaceuticals Corporation | $62.73 |
| Daiichi Sankyo Inc. | $56.35 |
| Array Biopharma Inc | $55.58 |
| Celgene Corporation | $50.68 |
| Food and Beverage | $735 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 8 companies. The companies reported $555,332 in research payments for these studies, mostly to the institutions running them.
- M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
AbbVie Inc. - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Beone Medicines Ltd. · Active, not recruiting · NCT04002297 - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Inc. · Active, not recruiting · NCT05578976 - A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Beone Medicines Ltd. · Active, not recruiting · NCT03336333 - Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)
AstraZeneca UK Limited - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular…
AbbVie Inc. - A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
Janssen Research & Development, LLC - A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.